CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 18 enrolled
Drug / intervention
MASL +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04188665
NCT04188665Early Ph 1Completed
CompareCT.gov

Using Maackia Amurensis Seed Lectin to Target the Podoplanin Receptor as a Functionally Relevant Biomarker to Inhibit the Growth of Oral Squamous Cell Carcinoma and Precancerous Lesions

Rowan University·interventional·Posted Dec 6, 2019·Updated Mar 20, 2026

In Brief

A Early Phase 1 clinical trial evaluating MASL and Placebo for Squamous Cell Carcinoma of Head and Neck. Completed, enrolled 18 participants across 4 sites.

Detailed Summary

This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Carcinoma of Head and Neck
CountriesUnited States
CollaboratorsRutgers University

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedDec 6, 2019
Enrollment StartJan 29, 2021
Primary CompletionDec 31, 2024
Study CompletionMay 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.6 years ago

Interventions

MASLdrug

Patients treated with MASL lozenge

Placeboother

Patients treated with placebo lozenge